An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

Roche

Status: Completed

Conditions: Breast Cancer

Treatments: Drug: Bevacizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT01215123

ML25100

Details and patient eligibility

About

This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data will be collected for approximately 24 months.

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin

Exclusion criteria

• Patients not willing or unable to signed written consent form

Trial design

28 participants in 1 patient group

Bevacizumab

Description:

Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.

Treatment:

Drug: Bevacizumab